Literature DB >> 2680427

Morbidity and mortality of portal hypertension.

J B Ready1, W G Rector.   

Abstract

Portal hypertension occurs in several aetiologically distinct disease states associated with either increased flow or increased resistance in the portal venous system. The morbidity and mortality observed are the result of ascites formation, impaired hepatic metabolism, encephalopathy and, most ominously, variceal haemorrhage. Patients with conditions in which there is relatively little hepatic parenchymal damage (non-cirrhotic portal hypertension) tend to have fewer episodes of encephalopathy and are better able to tolerate bleeding episodes than those patients with underlying cirrhosis. Similarly, the development of ascites varies with respect to the aetiology of the portal hypertension. This chapter discusses the natural history of the various disease states that manifest portal hypertension, thus allowing critical evaluation of the various therapeutic modalities used in its treatment.

Entities:  

Mesh:

Year:  1989        PMID: 2680427     DOI: 10.2165/00003495-198900372-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  105 in total

1.  Primary billiary cirrhosis (chronic intrahepatic obstructive jaundice).

Authors:  S SHERLOCK
Journal:  Gastroenterology       Date:  1959-11       Impact factor: 22.682

2.  A clinical investigation of the portacaval shunt. V. Survival analysis of the therapeutic operation.

Authors:  F C Jackson; E B Perrin; W R Felix; A G Smith
Journal:  Ann Surg       Date:  1971-10       Impact factor: 12.969

3.  Nodular regenerative hyperplasia of the liver. Report of six cases and review of the literature.

Authors:  P Rougier; C Degott; B Rueff; J P Benhamou
Journal:  Gastroenterology       Date:  1978-08       Impact factor: 22.682

4.  Viral hepatitis: clinical aspects.

Authors:  A G Redeker
Journal:  Am J Med Sci       Date:  1975 Jul-Aug       Impact factor: 2.378

5.  Hepatic veno-occlusive disease originating in Ecuador.

Authors:  C L Lyford; G G Vergara; D D Moeller
Journal:  Gastroenterology       Date:  1976-01       Impact factor: 22.682

6.  Clinical significance of antibody to the hepatitis delta virus in symptomless HBsAg carriers.

Authors:  S Arico; M Aragona; M Rizzetto; F Caredda; A Zanetti; G Marinucci; S Diana; P Farci; M Arnone; N Caporaso
Journal:  Lancet       Date:  1985-08-17       Impact factor: 79.321

7.  Post-transfusion chronic liver disease.

Authors:  R L Koretz; S C Suffin; G L Gitnick
Journal:  Gastroenterology       Date:  1976-11       Impact factor: 22.682

8.  Cirrhosis and diabetes. I. Increased incidence of diabetes in patients with Laennec's cirrhosis.

Authors:  H O Conn; W Schreiber; S G Elkington; T R Johnson
Journal:  Am J Dig Dis       Date:  1969-12

9.  Chronic hepatitis B antigenaemia in patients with hepatosplenic schistosomiasis.

Authors:  S Bassily; Z Farid; G I Higashi; I A Kamel; N A El-Masry; R H Watten
Journal:  J Trop Med Hyg       Date:  1979 Nov-Dec

10.  Improved survival following injection sclerotherapy for esophageal varices: final analysis of a controlled trial.

Authors:  D Westaby; B R Macdougall; R Williams
Journal:  Hepatology       Date:  1985 Sep-Oct       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.